Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial. (Record no. 3745)

MARC details
000 -LEADER
fixed length control field 04044nam a22004097a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 190724s20182018 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 2168-6149
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1001/jamaneurol.2018.2338 [doi]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 2696968 [pii]
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code PMC6583201 [pmc]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 30167675
245 ## - TITLE STATEMENT
Title Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial.
251 ## - Source
Source JAMA Neurology. 75(12):1494-1501, 2018 Dec 01.
252 ## - Abbreviated Source
Abbreviated source JAMA Neurol. 75(12):1494-1501, 2018 Dec 01.
253 ## - Journal Name
Journal name JAMA neurology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2018
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2019
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status ppublish
266 ## - Date added to catalog
Date added to catalog 2018-09-28
520 ## - SUMMARY, ETC.
Abstract Conclusions and Relevance: Treatment with dextroamphetamine combined with physical therapy did not improve recovery of motor function compared with placebo combined with physical therapy as assessed 3 months after hemispheric ischemic stroke. The studied treatment regimen was safe.
520 ## - SUMMARY, ETC.
Abstract Design, Setting, Participants: This pilot, double-blind, block-randomized clinical trial included patients with cortical or subcortical ischemic stroke and moderate or severe motor deficits from 5 rehabilitation hospitals or units. Participants were screened and enrolled from March 2001 through March 2003. The primary outcome was assessed 3 months after stroke. Study analysis was completed December 31, 2015. A total of 1665 potential participants were screened and 64 were randomized. Participants had to begin treatment 10 to 30 days after ischemic stroke. Data analysis was based on intention to treat.
520 ## - SUMMARY, ETC.
Abstract Importance: Data from animal models show that the administration of dextroamphetamine combined with task-relevant training facilitates recovery after focal brain injury. Results of clinical trials in patients with stroke have been inconsistent.
520 ## - SUMMARY, ETC.
Abstract Interventions: Participants were allocated to a regimen of 10 mg of dextroamphetamine (n = 32) or placebo (n = 32) combined with a 1-hour physical therapy session beginning 1 hour after drug or placebo administration every 4 days for 6 sessions in addition to standard rehabilitation.
520 ## - SUMMARY, ETC.
Abstract Main Outcomes and Measures: The primary outcome was the difference between groups in change in Fugl-Meyer motor scores from baseline to 3 months after stroke (intention to treat with dextroamphetamine). Secondary exploratory measures included the National Institutes of Health Stroke Scale, Canadian Neurological Scale, Action Research Arm Test, modified Rankin Scale score, Functional Independence Measure, Ambulation Speed and Distance, Mini-Mental State Examination, Beck Depression Inventory, and Stroke Impact Scale.
520 ## - SUMMARY, ETC.
Abstract Objectives: To collect data important for future studies evaluating the effect of dextroamphetamine combined with physiotherapy for improving poststroke motor recovery and to test the efficacy of the approach.
520 ## - SUMMARY, ETC.
Abstract Results: Among the 64 patients randomized to dextroamphetamine vs placebo (55% men; median age, 66 years; age range, 27-91 years), no overall treatment-associated difference in the mean (SEM) change in Fugl-Meyer motor scores from baseline to 3 months after stroke was noted (-18.65 [2.27] points with dextroamphetamine vs -20.83 [2.94] points with placebo; P = .58). No overall treatment-associated differences in any of the study's secondary measures and no differences in subgroups based on stroke location or baseline severity were found. No adverse events were attributed to study treatments.
520 ## - SUMMARY, ETC.
Abstract Trial Registration: ClinicalTrials.gov identifier: NCT01905371.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar National Rehabilitation Network
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Dromerick, Alexander W
790 ## - Authors
All authors Dromerick AW, Goldstein LB, Good DC, Lennihan L, Pura J, Rabadi MJ, Reding MJ, Samsa GP
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1001/jamaneurol.2018.2338">https://dx.doi.org/10.1001/jamaneurol.2018.2338</a>
Public note https://dx.doi.org/10.1001/jamaneurol.2018.2338
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 09/28/2018   30167675 30167675 09/28/2018 09/28/2018 Journal Article

Powered by Koha